Eroid realization.Biomedicines 2021, 9,20 ofConflicts of Interest: The authors declare no conflict of interest. The funders had no function in the style on the study; in the collection, analyses, or interpretation of data; within the writing from the manuscript, or in the decision to publish the outcomes.
biomedicinesReviewDysfunction in the Cystic 1-Oleoyl lysophosphatidic acid Activator Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Prospective Target for Personalised MedicineLaura Carrasco-Hern dez 1,two , Esther Quintana-Gallego 1,2 , Carmen Calero 1,two , Roc Reinoso-Arija 1 , Borja Ruiz-Duque 1 and JosLuis L ez-Campos 1,two, Unidad M ico-Quir gica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc /Universidad de Sevilla, 41013 Sevilla, Spain; [email protected] (L.C.-H.); [email protected] (E.Q.-G.); [email protected] (C.C.); [email protected] (R.R.-A.); [email protected] (B.R.-D.) Centro de Investigaci Biom ica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain Correspondence: [email protected]: Carrasco-Hern dez, L.; Quintana-Gallego, E.; Calero, C.; Reinoso-Arija, R.; Ruiz-Duque, B.; L ez-Campos, J.L. Dysfunction within the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Illness as a Possible Target for Personalised Medicine. Biomedicines 2021, 9, 1437. https:// 9101437 Academic Editor: Alice M. Turner Received: 31 July 2021 Accepted: 7 TC LPA5 4 Description October 2021 Published: ten OctoberAbstract: In recent years, several pathways were explored in the pathogenesis of COPD in the quest for new possible therapeutic targets for much more personalised health-related care. In this context, the study on the cystic fibrosis transmembrane conductance regulator (CFTR) started to achieve value, particularly since the advent with the new CFTR modulators which had the prospective to appropriate this protein’s dysfunction in COPD. The CFTR is an ion transporter that regulates the hydration and viscosity of mucous secretions inside the airway. For that reason, its abnormal function favours the accumulation of thicker and much more viscous secretions, reduces the periciliary layer and mucociliary clearance, and produces inflammation within the airway, as a consequence of a bronchial infection by each bacteria and viruses. Identifying CFTR dysfunction inside the context of COPD pathogenesis is key to completely understanding its function within the complex pathophysiology of COPD as well as the possible from the different therapeutic approaches proposed to overcome this dysfunction. In specific, the prospective from the rehydration of mucus and the function of antioxidants and phosphodiesterase inhibitors needs to be discussed. Furthermore, the modulatory drugs which enhance or restore decreased levels with the protein CFTR had been not too long ago described. In distinct, two CFTR potentiators, ivacaftor and icenticaftor, had been explored in COPD. The present evaluation updated the pathophysiology with the complicated function of CFTR in COPD along with the therapeutic solutions which could possibly be explored. Keywords and phrases: cystic fibrosis transmembrane conductance regulator; COPD; CFTR modulators; ivacaftor; icenticaftorPublisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.1. Introduction Despite the considerable advances created in current years, the mechanisms underlying the onset, pathogenesis and symptomatic improvement of chronic obst.